Abedi Mina, Alavi-Moghadam Sepideh, Payab Moloud, Goodarzi Parisa, Mohamadi-Jahani Fereshteh, Sayahpour Forough Azam, Larijani Bagher, Arjmand Babak
Cell Therapy and Regenerative Medicine Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Metabolomics and Genomics Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Cell Regen. 2020 Dec 1;9(1):20. doi: 10.1186/s13619-020-00058-0.
Systemic sclerosis is a rare chronic autoimmune disease with extensive microvascular injury, damage of endothelial cells, activation of immune responses, and progression of tissue fibrosis in the skin and various internal organs. According to epidemiological data, women's populations are more susceptible to systemic sclerosis than men. Until now, various therapeutic options are employed to manage the symptoms of the disease. Since stem cell-based treatments have developed as a novel approach to rescue from several autoimmune diseases, it seems that stem cells, especially mesenchymal stem cells as a powerful regenerative tool can also be advantageous for systemic sclerosis treatment via their remarkable properties including immunomodulatory and anti-fibrotic effects. Accordingly, we discuss the contemporary status and future perspectives of mesenchymal stem cell transplantation for systemic sclerosis.
系统性硬化症是一种罕见的慢性自身免疫性疾病,伴有广泛的微血管损伤、内皮细胞损伤、免疫反应激活以及皮肤和各种内脏器官的组织纤维化进展。根据流行病学数据,女性人群比男性更容易患系统性硬化症。到目前为止,人们采用了各种治疗方法来控制该疾病的症状。由于基于干细胞的治疗已发展成为一种治疗多种自身免疫性疾病的新方法,干细胞,尤其是间充质干细胞作为一种强大的再生工具,似乎因其包括免疫调节和抗纤维化作用在内的显著特性,也有利于系统性硬化症的治疗。因此,我们讨论了间充质干细胞移植治疗系统性硬化症的现状和未来前景。